Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Posted on by

STOCKHOLM, Sept. 13, 2024 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved…